Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TH-SC01 for Radiation-induced Rectal Injury
NCT05939778Phase 1Recruiting
- Sponsor
- Jinling Hospital
- Start
- Sep 2022
- Primary completion
- Jan 2024
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TH-SC01 in radiation-induced rectal injury, sponsored by Jinling Hospital. Primary endpoints: LENT-SOMA Scale Score Improvement at 16 weeks and Incidence of Treatment Emergent Adverse-Events. Started Sep 2022; status: recruiting.
02
Drugs
TH-SC01
03
Conditions
radiation-induced rectal injury
Beyond the preview
Go deeper on NCT05939778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05939778.